NCT01537133View on ClinicalTrials.gov

Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
AsthmaAtopy
Interventions
DRUG

fluticasone

Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day

DRUG

Placebo

Dry Powder Inhaler: Placebo

Trial Locations (9)

15213

University of Pittsburgh, Adult, Pittsburgh

27110

Duke University School of Medicine, Durham

27157

Wake Forest University Health Sciences, Winston-Salem

53972

University of Wisconsin, Madison

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University, St Louis

80206

National Jewish Health, Denver

94143-0130

University of California, San Francisco, Adult, San Francisco

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Milton S. Hershey Medical Center

OTHER

NCT01537133 - Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment | Biotech Hunter | Biotech Hunter